Epidemiological, Clinicopathological and Prognosis Features of Moroccan Patients with Nasopharyngeal Carcinoma.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 May 2023
Historique:
received: 15 03 2022
medline: 31 5 2023
pubmed: 29 5 2023
entrez: 29 5 2023
Statut: epublish

Résumé

A distinct epidemiology, etiology, clinical characteristics, and therapeutic outcomes characterize nasopharyngeal carcinoma (NPC) from other head and neck cancers. An actualized analysis of NPC patients' features enables a global view of NPC management. Accordingly, the current study investigated the epidemiological and clinical characteristics of Moroccan patients with NPC, as well as their 4-years survival outcomes and influencing prognostic factors. We prospectively analyzed data of 142 histologically confirmed Moroccan patients with NPC between October 2016 and February 2019. Kaplan-Meier and Cox regression analyses were used to assess predictive prognostic factors related to NPC. All analyses were conducted using SPSS version 21 statistical software. In the present study, a net male predominance was found, with a mean age of 44±16.3 years old. Advanced stages of NPC were observed in 64.1% of patients, and 32.4% of patients presented with distant metastasis at diagnosis. The 4-years overall survival, locoregional relapse-free survival, distant metastasis-free survival and progression-free survival were 68.0%, 63.0%, 53.9%, and 39.9%, respectively. Age, N category and distant metastasis were identified as the most important independent prognosis factors for NPC in this cohort (p<0.05). In conclusion, NPC affects young adults and is frequently diagnosed at advanced disease stages, impacting therefore negatively patients survival; which is in line with data from endemic areas for NPC. The current study clearly highlights that a greater attention should be directed to improving the management of this aggressive malignancy.

Identifiants

pubmed: 37247266
doi: 10.31557/APJCP.2023.24.5.1477
pmc: PMC10495879
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1477-1486

Références

Chin J Cancer. 2016 May 05;35:41
pubmed: 27146632
Chin J Cancer. 2015 May 14;34(8):350-7
pubmed: 26058679
BMC Cancer. 2013 May 04;13:226
pubmed: 23642234
Cancer Med. 2020 Sep;9(17):6147-6158
pubmed: 32649056
Sci Rep. 2016 Jan 18;6:19290
pubmed: 26776301
Viruses. 2022 Dec 25;15(1):
pubmed: 36680107
Rev Med Liege. 2019 May;74(5-6):349-353
pubmed: 31206279
Lancet. 2005 Jun 11-17;365(9476):2041-54
pubmed: 15950718
J Oncol. 2019 Nov 29;2019:4094395
pubmed: 31871457
Int J Cancer. 2000 Feb 1;85(3):364-9
pubmed: 10652428
Osong Public Health Res Perspect. 2016 Dec;7(6):360-372
pubmed: 28053841
Eur J Cancer. 2003 Jul;39(11):1535-41
pubmed: 12855259
Cancer Metastasis Rev. 2017 Sep;36(3):411-423
pubmed: 28801840
Cancer Causes Control. 2015 Jun;26(6):913-21
pubmed: 25822573
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1035-1047
pubmed: 33849968
CA Cancer J Clin. 2016 Jul;66(4):337-50
pubmed: 26891458
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Otolaryngol Head Neck Surg. 2016 Aug;155(2):274-80
pubmed: 27143706
Chin J Cancer. 2010 Feb;29(2):145-50
pubmed: 20109341
Anticancer Drugs. 2015 Nov;26(10):1017-25
pubmed: 26241803
J Radiat Res. 2000 Oct;41 Suppl:53-62
pubmed: 11142212
Semin Cancer Biol. 2012 Apr;22(2):96-106
pubmed: 22313875
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1107-16
pubmed: 15752890
Ann Nucl Med. 2022 Oct;36(10):876-886
pubmed: 35836088
Semin Cancer Biol. 2012 Apr;22(2):117-26
pubmed: 22311401
Int J Biol Sci. 2018 Apr 5;14(5):549-556
pubmed: 29805306
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77
pubmed: 17035381
Radiat Oncol. 2014 Dec 05;9:274
pubmed: 25477058
Eur J Med Chem. 2020 Dec 1;207:112758
pubmed: 32858472
Saudi Med J. 2004 Nov;25(11):1579-82
pubmed: 15573182
Chin Clin Oncol. 2016 Apr;5(2):16
pubmed: 27121876
Eur J Cancer. 2003 Nov;39(16):2349-54
pubmed: 14556927
Lancet Oncol. 2015 Jun;16(6):645-55
pubmed: 25957714
Malays J Med Sci. 2009 Oct;16(4):50-4
pubmed: 22135512
Semin Radiat Oncol. 2012 Jul;22(3):233-44
pubmed: 22687948
Br J Cancer. 2013 Aug 6;109(3):788-94
pubmed: 23807164
Infect Agent Cancer. 2021 Feb 18;16(1):15
pubmed: 33602309
Ann Transl Med. 2019 Dec;7(23):768
pubmed: 32042784
PLoS One. 2015 May 12;10(5):e0126108
pubmed: 25965270
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2285-94
pubmed: 24252872
Ann Oncol. 2021 Apr;32(4):452-465
pubmed: 33358989
Eur J Cancer. 2013 Jan;49(1):150-5
pubmed: 22892061
Eur J Cancer. 2003 Oct;39(15):2121-35
pubmed: 14522369
Oncotarget. 2015 Sep 15;6(27):24511-21
pubmed: 26087194
Am J Epidemiol. 2013 Aug 1;178(3):325-38
pubmed: 23785114
Oncotarget. 2017 Oct 24;8(57):97323-97330
pubmed: 29228613
BMC Cancer. 2015 Nov 16;15:906
pubmed: 26573573

Auteurs

Amina Gihbid (A)

Laboratory of Viral Oncology, Institut Pasteur du Maroc, Casablanca, Morocco.
Laboratory of Pathophysiology, Molecular Genetics and Biotechnology, Faculty of Sciences Ain Chock, Hassan II University, Casablanca, Morocco.

Nezha Tawfiq (N)

Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco.

Nadia Benchakroun (N)

Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco.

Zineb Bouchbika (Z)

Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco.

Souha Sahraoui (S)

Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco.

Karima Bendahhou (K)

Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco.

Abdelatif Benider (A)

Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco.

Jaafar Ibnohoud (J)

Nuclear Medicine Department, Ibn Rochd University Hospital, Hassan II University, Casablanca, Morocco.

Amal Guensi (A)

Nuclear Medicine Department, Ibn Rochd University Hospital, Hassan II University, Casablanca, Morocco.

Mohammed El Mzibri (M)

Biology and Medical Research Unit, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco.

Rachida Cadi (R)

Laboratory of Pathophysiology, Molecular Genetics and Biotechnology, Faculty of Sciences Ain Chock, Hassan II University, Casablanca, Morocco.

Meriem Khyatti (M)

Laboratory of Viral Oncology, Institut Pasteur du Maroc, Casablanca, Morocco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH